Heliene Celebrates the Grand Opening of Rogers, MN Solar Manufacturing Facility
ROGERS, Minn., June 02, 2025 (GLOBE NEWSWIRE) -- Heliene, Inc., a customer-first provider of North American-made solar PV modules, celebrated the grand opening of a new solar PV module manufacturing facility in Rogers, MN on May 30. U.S. Senator Amy Klobuchar, MN Commissioner Matt Varilek, and Rogers' Major Shannon Klick together with other State elected officials were in attendance to mark this milestone achievement for domestic clean energy manufacturing, regional job creation, and economic development.
The Rogers facility houses Minnesota Line 3, Heliene's third U.S.-based manufacturing line. Minnesota Line 3 has been operational since April 29 and has an annual capacity of 500MW. Heliene also owns and operates 300MW-Minnesota Line 1 and 500MW-Minnesota Line 2 at its existing Mountain Iron, MN facility. The opening of Line 3 brings Heliene's total U.S.-made module manufacturing output per year to 1.3GW.
'Heliene is experiencing continued demand for our high-quality, high-domestic content solar PV modules,' said Martin Pochtaruk, CEO of Heliene. 'By nearly doubling our manufacturing capacity at our new Rogers, Minnesota facility, we can continue to provide best-in-class fully domestic content products and service to our customers, while we deliver on our broader goal of onshoring U.S. solar supply chains, by incorporating domestically-produced, cells, frames, polymers and other critical components.'
The completion of Minnesota Line 3 expands Heliene's commitment to offering U.S. solar developers high-quality PV modules made with an industry-leading percentage of domestic content. The Company is hiring more than 220 new employees in the greater Minneapolis-St. Paul metropolitan area to support operations, maintenance, and engineering at the new facility. Heliene received $2.3M in funding from the Minnesota Department of Employment and Economic Development (DEED), with specific funding from the Minnesota Investment Fund (MIF), Minnesota Job Creation Fund (JCF) and the Minnesota Job Skills Partnership (MJSP), to support the above mentioned job creation.
'The opening of this new manufacturing plant means high-quality solar panels will be produced in Rogers to meet increasing demand for energy across our state and throughout the country—and it will create hundreds of new jobs for the region,' said Senator Klobuchar. 'I'm committed to working together to strengthen our manufacturing economy, increase affordable clean energy, and bring the jobs of the future to Minnesota.'
Across all its U.S. manufacturing lines, Heliene is producing bifacial, high-efficiency crystalline solar PV modules with the highest possible percentage of domestic content available on the market. To support this effort, Heliene has secured a number of strategic partnerships with domestic solar module component manufacturers in recent years.
About HelieneHeliene is one of North America's fastest-growing, domestic PV manufacturers serving the utility-scale, commercial, and residential markets. With an in-house logistics team and remarkably responsive support staff, Heliene delivers competitively priced, high performance solar modules precisely when and where customers need them to accelerate North America's clean energy transition. Founded in 2010, Heliene consistently ranks as a highly bankable module manufacturer. For more information, visit www.heliene.com.
For more information, please contact:HelieneMedia inquiries:heliene@fischtankpr.com646-699-1414
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
San Francisco Chronicle
an hour ago
- San Francisco Chronicle
Salarius: Q2 Earnings Snapshot
HOUSTON (AP) — HOUSTON (AP) — Salarius Pharmaceuticals, Inc. (SLRX) on Tuesday reported a loss of $958,000 in its second quarter. The Houston-based company said it had a loss of 45 cents per share. _____
Business Wire
2 hours ago
- Business Wire
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended June 30, 2025. Recent Business Highlights Soft Tissue Ablation Expanded the pilot program for the nsPFA Percutaneous Electrode for soft tissue ablation. Treated over 140 Benign Thyroid Nodule patients to date across multiple pilot program centers. Identified five sites to participate in a post-market study of the treatment of benign thyroid disease, with plans to commence enrollment in Q3 upon receipt of IRB approvals. Surgical AF Ablation Submitted FDA IDE application, including the pivotal study protocol, to support a premarket approval (PMA) application for the treatment of atrial fibrillation (AF) and remain on track to commence the IDE pivotal study in the next few months. Treated 40 patients to date and generated positive clinical outcomes, as indicated by follow up remapping procedures, as part of the nsPFA Cardiac Surgery System multi-center, first-in-human AF feasibility study in Europe. Endocardial Catheter AF Ablation Submitted FDA IDE application, including the pivotal study protocol, and remain on track to commence the IDE pivotal study in the next few months. Observed improved procedure times since last presented at the Heart Rhythm Society 2025 Meeting in April. Treated over 140 total patients with the nsPFA 360° catheter to date as part of the multi-center, first-in-human AF study in Europe. 'We are advancing the top priorities established at the beginning of 2025 for each of our three market development programs,' said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences. 'I am delighted to announce that we have expanded the pilot program for the Percutaneous Electrode for soft tissue ablation, submitted our IDE for both the cardiac surgical clamp and nsPFA 360° catheter, all while continuing to treat more patients and generate positive clinical outcomes with our cardiac devices in their respective feasibility studies in Europe. These achievements further reinforce the transformational potential of nsPFA energy for treating benign thyroid disease, AF and additional diseases in the future.' Second Quarter 2025 Financial Results Total GAAP costs and expenses, representing research and development and general and administrative expenses, for the three months ended June 30, 2025, were $20.3 million, an increase of $8.5 million compared to $11.7 million in the prior year period. The increase was primarily driven by administrative expenses related to the expanding organization to support advancement of the nsPFA device clinical trials and commercialization, and non-cash stock-based compensation and other compensation. Non-GAAP costs and expenses for the three months ended June 30, 2025, were $14.8 million, an increase of $5.4 million compared to $9.4 million in the prior year period. GAAP net loss for the three months ended June 30, 2025 was ($19.2) million compared to ($11.4) million for the three months ended June 30, 2024. Non-GAAP net loss for the three months ended June 30, 2025 was ($13.7) million compared to ($9.0) million for the three months ended June 30, 2024. Cash and cash equivalents totaled $106.3 million as of June 30, 2025, compared to $26.2 million as of June 30, 2024 and $119.3 million as of March 31, 2025. Cash used in operating activities in the second quarter of 2025 totaled $12.8 million, compared to $8.4 million used in the same period in the prior year, and $13.5 million used in the first quarter of 2025. Reconciliations of GAAP to Non-GAAP cost and expenses and net loss have been provided in the tables following the financial statements in this press release. An explanation of these measures is also included below under the heading 'Non-GAAP Financial Measures.' Webcast and Conference Call Information Pulse Biosciences' management will host a conference call today, August 12, 2025, beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 or 1-646-307-1963 and providing passcode 2036874. A live and recorded webcast of the event will be available at About Pulse Biosciences ® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company's proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries. Non-GAAP Financial Measures In this press release, in order to supplement the Company's condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance. Company management uses these measurements as aids in monitoring the Company's ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for financial and operational decision-making. Non-GAAP adjustments include stock-based compensation, depreciation and amortization, restructuring, severance, and a legal settlement. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to management and investors. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Investors are encouraged to review these reconciliations, and not to rely on any single financial measure to evaluate the Company's business. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies, which could reduce the usefulness of the Company's non-GAAP financial measures as tools for comparison. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures in this earnings release exclude non-cash expenses for stock-based compensation, depreciation and amortization, restructuring costs, severance expense and legal settlement expenses. Forward-Looking Statements All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the effectiveness of the Company's nsPFA technology and CellFX System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company's future commercialization and product development efforts and whether those efforts will be successful, statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device, such as the nsPFA 360° Cardiac Catheter System, the nsPFA Cardiac Surgical System, and the nsPFA Percutaneous Electrode System, and statements concerning the Company's future clinical and regulatory initiatives anywhere in the world, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences' current expectations, estimates, and projections regarding Pulse Biosciences' business, operations and other similar or related factors. Words such as 'may,' 'will,' 'could,' 'would,' 'should,' 'anticipate,' 'predict,' 'potential,' 'continue,' 'expects,' 'intends,' 'plans,' 'projects,' 'believes,' 'estimates,' and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences' control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences' filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available. PULSE BIOSCIENCES, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except per share amounts) (Unaudited) Three-Month Periods Ended Six-Month Periods Ended June 30, June 30, 2025 2024 2025 2024 Revenues: Product revenues $ — $ — $ — $ — Total revenues — — — — Cost and expenses: Research and development 12,088 7,230 22,401 13,971 General and administrative 8,187 4,496 15,918 8,370 Total cost and expenses 20,275 11,726 38,319 22,341 Loss from operations (20,275 ) (11,726 ) (38,319 ) (22,341 ) Other income: Interest income, net 1,107 343 2,356 821 Total other income 1,107 343 2,356 821 Net loss (19,168 ) (11,383 ) (35,963 ) (21,520 ) Comprehensive loss $ (19,168 ) $ (11,383 ) $ (35,963 ) $ (21,520 ) Net loss per share: Basic and diluted net loss per share $ (0.28 ) $ (0.20 ) $ (0.54 ) $ (0.38 ) Weighted average shares used to compute net loss per common share — basic and diluted 67,276 57,180 67,201 57,152 Expand Reconciliation of GAAP to Non-GAAP Financial Measures The following table presents the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures: (In thousands) (Unaudited) Three-Month Periods Ended Six-Month Periods Ended June 30, June 30, 2025 2024 2025 2024 Reconciliation of GAAP to non-GAAP Research and development: GAAP Research and development $ 12,088 $ 7,230 $ 22,401 $ 13,971 Less: Stock-based compensation expense (2,335 ) (1,001 ) (5,097 ) (1,950 ) Less: Depreciation and amortization (44 ) (52 ) (90 ) (105 ) Non-GAAP Research and development $ 9,709 $ 6,177 $ 17,214 $ 11,916 Reconciliation of GAAP to non-GAAP General and administrative: GAAP General and administrative $ 8,187 $ 4,496 $ 15,918 $ 8,370 Less: Stock-based compensation expense (2,854 ) (1,051 ) (5,773 ) (1,861 ) Less: Depreciation and amortization (229 ) (246 ) (466 ) (492 ) Add: Legal settlement — — 590 — Non-GAAP General and administrative $ 5,104 $ 3,199 $ 10,269 $ 6,017 Reconciliation of GAAP to non-GAAP Cost and expenses: GAAP Cost and expenses $ 20,275 $ 11,726 $ 38,319 $ 22,341 Less: Stock-based compensation expense (5,189 ) (2,052 ) (10,870 ) (3,811 ) Less: Depreciation and amortization (273 ) (298 ) (556 ) (597 ) Add: Legal settlement — — 590 — Non-GAAP Cost and expenses $ 14,813 $ 9,376 $ 27,483 $ 17,933 Reconciliation of GAAP to non-GAAP Net loss: GAAP Net loss $ (19,168 ) $ (11,383 ) $ (35,963 ) $ (21,520 ) Add: Stock-based compensation expense 5,189 2,052 10,870 3,811 Add: Depreciation and amortization 273 298 556 597 Less: Legal settlement — — (590 ) — Non-GAAP Net loss $ (13,706 ) $ (9,033 ) $ (25,127 ) $ (17,112 ) Expand
Business Wire
2 hours ago
- Business Wire
Superior Plus Declares 2025 Third Quarter Dividend
TORONTO--(BUSINESS WIRE)--Superior Plus Corp. (' Superior ' or ' the company') (TSX: SPB) announced today that its Board of Directors has approved a quarterly dividend of CAD $0.045 per common share payable on October 15, 2025, to shareholders of record at the close of business September 29, 2025. Superior's annualized cash dividend rate is currently CAD $0.18 per share. This dividend is an eligible dividend for Canadian income tax purposes. About Superior Plus Superior is a leading North American distributor of propane, compressed natural gas, renewable energy and related products and services, servicing approximately 750,000 customer locations in the U.S. and Canada. Through its primary businesses, propane distribution and CNG, RNG and hydrogen distribution, Superior safely delivers low carbon1 fuels to residential, commercial, utility, agricultural and industrial customers not connected to a pipeline. By displacing more carbon intensive fuels, Superior is a leader in the energy transition and helping customers lower operating costs and improve environmental performance. 1 Superior defines 'low carbon' and 'lower carbon' fuels as those with a lower carbon intensity than fossil fuels that may be utilized in the same application (e.g. diesel, gasoline). Forward-Looking Information This news release contains certain forward-looking information and statements based on Superior's current expectations, estimates, projections and assumptions in light of its experience and perception of historical trends. In this news release, such forward-looking information and statements can be identified by terminology such as 'will', "expects", "annualized", and similar expressions. In particular, this news release contains forward-looking statements and information relating to: future dividends, which may be declared on Superior's common shares; the timing and the amount of such dividend payments; and the expected tax treatment thereof. These forward-looking statements are being made by Superior based on certain assumptions that Superior has made in respect thereof as at the date of this news release regarding, among other things: the success of Superior's operations; prevailing commodity prices, margins, volumes and exchange rates; that Superior's future results of operations will be consistent with past performance and management expectations in relation thereto; the continued availability of capital at attractive prices to fund future capital requirements; future operating costs; that any required commercial agreements can be reached; that all required regulatory and environmental approvals can be obtained on the necessary terms promptly. These forward-looking statements are not guarantees of future performance and are subject to several known and unknown risks and uncertainties, including, but not limited to: the regulatory environment and decisions; non-performance of agreements in accordance with their terms; the impact of competitive entities and pricing; reliance on key industry partners and agreements; actions by governmental or regulatory authorities including changes in tax laws and treatment, or increased environmental regulation; adverse general economic and market conditions in Canada, North America and elsewhere; fluctuations in operating results; labour and material shortages; and certain other risks detailed from time to time in Superior's public disclosure documents including, among other things, those detailed under the heading "Risk Factors" in Superior's management's discussion and analysis and annual information form for the year ended December 31, 2024, which can be found at Accordingly, readers are cautioned that events or circumstances could cause results to differ materially from those predicted, forecasted or projected. Such forward-looking statements are expressly qualified by the above statements. Superior does not undertake any obligation to publicly update or revise any forward looking statements or information contained herein, except as required by applicable laws.
